Evaluation of the Pharmacokinetics and Safety of VX 548 in Participants With Severe Renal Impairment
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability
of VX-548 and its metabolite in participants with severe renal impairment and healthy
participants.